Clinical trial and in-vitro study comparing the efficacy of treating bony lesions with allografts versus synthetic or highly-processed xenogeneic bone grafts

• DOI: 10.1186/s12891-016-0930-1
• Publication Date: 2016-02-12T23:03:46Z
• Authors: Eva Johanna Kubosch; Anke Bernstein; Laura Wolf; Tobias Fretwurst; Katja Nelson; Hagen Schmal
• Keywords: Osteopontin; Cancellous bone

Our study aim was to compare allogeneic cancellous bone (ACB) and synthetic or highly-processed xenogeneic substitutes (SBS) in the treatment of skeletal defects orthopedic surgery. 232 patients treated for bony lesions with ACB (n = 116) SBS within a 10-year time period were included this case–control study. Furthermore, both materials seeded human osteoblasts (hOB, n 10) analyzed by histology, viability (AlamarBlue®) protein expression activity (Luminex®). The complication rate 14.2 %, proportion without healing 3.6 %; neither outcome parameter differed comparing intervention groups. Failed consolidation correlated an increase complications (p < 0.03). further highly significant association location use 0.001), but did not depend on age, ASA risk classification, BMI, smoking behavior type insurance. However, those factors significantly influence 0.02). Complication rates independent gender filling substances employed different locations. Histological examination revealed similar structures, whereas cell remnants apparent only allografts. Both biocompatible in-vitro, osteoblasts. cells remained vital over 3-week culture produced microscopically typical matrix. We observed initially increased osteocalcin, osteopontin, osteoprotegerin as well leptin adiponectin secretion declining after 1 week, especially group. Although investigated appeared be similarly suitable in-vivo decisively influenced other such site epidemiological parameters.